FBIO Priority Review Voucher Sale: $205M Cyprium PRV Analysis

What Is a Priority Review Voucher?

A Priority Review Voucher (PRV) is a transferable voucher awarded by the FDA to companies that receive approval for treatments of rare pediatric diseases, neglected tropical diseases, or medical countermeasures. The voucher entitles its holder — or any party it is sold to — to a Priority Review designation on a future FDA application, reducing the standard review timeline from approximately 12 months to approximately 6 months.

PRVs are valuable to large pharmaceutical companies with blockbuster drugs in their pipelines because an accelerated review can translate to months of additional market exclusivity. PRV sale prices have historically ranged from approximately $68 million to $350 million, depending on market conditions and buyer demand.

ZYCUBO Approval and PRV Award

On January 12, 2026, the FDA approved ZYCUBO (copper histidinate) injection for the treatment of Menkes disease in pediatric patients. Menkes disease is a rare X-linked recessive disorder of copper metabolism that primarily affects male infants and can be fatal without treatment. ZYCUBO is the first FDA-approved therapy specifically indicated for Menkes disease.

Because Menkes disease qualifies as a rare pediatric disease, the approval of ZYCUBO entitled Cyprium Therapeutics to receive a Rare Pediatric Disease Priority Review Voucher from the FDA under the Creating Hope Act (Section 529 of the FD&C Act).

PRV Sale Financial Breakdown

Under the terms of its licensing agreement, Cyprium is obligated to pay the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 20% of the proceeds from any sale of the Priority Review Voucher. NICHD supported the early development of copper histidinate for Menkes disease.

Fortress Biotech — Cyprium Ownership Structure

Cyprium Therapeutics is a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO). Fortress Biotech holds an approximately 76% economic interest in Cyprium. The remaining interest is held by other parties including management and early investors.

Because Fortress does not own 100% of Cyprium, the PRV sale proceeds flow to Cyprium first, and Fortress's share is proportional to its ownership interest, subject to the terms of intercompany agreements and Cyprium's own obligations (including the NICHD payment).

Oaktree Debt Facility

Fortress Biotech has an outstanding debt facility with Oaktree Capital Management. As of recent SEC filings, the outstanding balance is approximately $29.5 million, with the maturity extended to June 2028. The terms of any mandatory prepayment or debt reduction from PRV proceeds have not been publicly detailed as of this writing.

ZYCUBO Commercial Milestones

Separate from the PRV sale, Cyprium retains the commercial rights to ZYCUBO and is eligible for additional milestone payments and royalties based on net sales performance.

Key Dates

PRV Market Context

The $205 million sale price falls within the historical range for Priority Review Voucher transactions. PRV prices have varied significantly based on supply and demand dynamics. Recent transactions have generally been in the $100M–$150M range, making the $205M price noteworthy as it sits above the recent average.

The PRV program was established under the Creating Hope Act and has been extended multiple times by Congress. It provides a financial incentive for pharmaceutical companies to develop treatments for rare pediatric diseases that might not otherwise justify the development investment on commercial grounds alone.

Sources

This analysis is compiled from publicly available sources including:

• Fortress Biotech SEC 8-K filing (February 2026)
• Cyprium Therapeutics / Fortress Biotech press releases via GlobeNewsWire
• FDA approval announcement for ZYCUBO (January 12, 2026)
• Fortress Biotech SEC filings (10-K, 10-Q) for debt and ownership disclosures